Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer

• Status: Recruiting
• Trial end date: 2024-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

In this study, The researchers sought to explore the efficacy and safety of involving field radiotherapy in the oligo-metastatic/recurrent/refractory ovarian cancer patients among different groups which include drug therapy alone, radiotherapy alone, and drug therapy plus radiotherapy by inviting clinical multi-center participation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Health Science Center of Xi'an Jiaotong University
• Treatments: Coal Tar

Criteria

Inclusion Criteria:

1. Age ≥18;

2. Evidence of histological diagnosis of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)

3. Pathology or imaging suggested recurrence, with measurable lesions, and the number of lesions ≤3;

4. No serious hematopoietic dysfunction, abnormal heart, lung, liver, kidney and immune deficiency

5. Cooperative Oncology Group-Status (ECOG Status) score 0-2;

6. Expected survival ≥3 months;

7. Feasible abdomen and pelvic cavity MRI/CT;

8. Good compliance, signed informed consent voluntarily.

Exclusion Criteria:

1. Previous radiotherapy at the target lesion site;

2. History of active inflammatory bowel disease or severe stomach and duodenal ulcers;

3. Human immunodeficiency virus (HIV) infected persons;

4. active hepatitis b (HBVDNA quantitative test results exceed the lower limit), or HCV infection (HCVRNA quantitative test results exceed the lower limit);

5. suffering from serious underlying diseases, including but not limited to active infections requiring systemic medication:

6. patients with a history of other malignant tumors (except cured basal cell carcinoma of the skin);

7. neurological or mental disorders that affect cognitive ability;

8. Patients whose lesions have been evaluated by the investigator and cannot be treated with external irradiation or endovascular radiation therapy;

9. those who cannot follow up regularly as prescribed by the doctor;

10. Other reasons not suitable for participating in this study as judged by the researcher.